Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Company Overview

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders. Its candidates are designed to deliver therapeutic genetic material to affected cells, with the goal of addressing the underlying causes of disease rather than treating symptoms alone. The company’s therapies remain investigational and are subject to clinical and regulatory review.

Founded in 2019 and headquartered in Dallas, Texas, Taysha was established in collaboration with researchers at UT Southwestern Medical Center. The company’s operations are primarily focused on advancing its pipeline through clinical development and regulatory processes in the United States, with potential global applications for rare neurological diseases. R.A. Session serves as president and chief executive officer.

Key Stats

• Today's Range: $4.63 to $4.86
• 50-Day Range: $4.63 to $6.68
• 52-Week Range: $3.69 to $7.30
• Volume: 2.56 million shs
• Average Volume: 4.04 million shs
• Market Capitalization: $1.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.77
• Consensus Rating: Buy

Taysha Gene Therapies Stock Analysis - MarketRank™

Taysha Gene Therapies scored higher than 51% of companies evaluated by MarketBeat, and ranked 494th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Taysha Gene Therapies has a consensus price target of $12.77, representing about 175.8% upside from its current price of $4.63.

Amount of Analyst Coverage

Taysha Gene Therapies has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.52) to ($0.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Taysha Gene Therapies is -11.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Taysha Gene Therapies is -11.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Taysha Gene Therapies has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.35% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 18.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Taysha Gene Therapies has recently increased by 9.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Taysha Gene Therapies does not currently pay a dividend.

Dividend Growth

Taysha Gene Therapies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.37

News Sentiment

Taysha Gene Therapies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

7 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Taysha Gene Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,248,000.00 in company stock.

Percentage Held by Insiders

3.48% of the stock of Taysha Gene Therapies is held by insiders.

Percentage Held by Institutions

77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TSHA
• CIK: 1806310
• Web: www.tayshagtx.com
• Phone: 214-612-0000
• Fax: N/A
• Employees: 99
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Taysha Gene Therapies: $12.77
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: +175.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109 million
• Net Margins: N/A
• Pretax Margin: -2,728.04%
• Return on Equity: -56.19%
• Return on Assets: -41.84%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 17.76
• Quick Ratio: 17.76

Sales & Book Value

• Annual Sales: $9.77 million
• Price / Sales: 154.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 5.14

Miscellaneous

• Outstanding Shares: 325,830,000
• Free Float: 314,495,000
• Market Cap: $1.51 billion
• Optionable: Optionable
• Beta: 1.19